FeNO non-suppression identifies corticosteroid-resistant type-2 signaling in severe asthma

FeNO non-suppression identifies corticosteroid-resistant type-2 signaling in severe asthma

Veure altres versions (1)

Dades bibliogràfiques
Autors principals:	Couillard, S, Shrimanker, R, Chaudhuri, R, Mansur, AH, McGarvey, LP, Heaney, LG, Fowler, SJ, Bradding, P, Pavord, ID, Hinks, TSC
Format:	Conference item
Idioma:	English
Publicat:	BMJ Publishing Group 2021

Ítems similars

FeNO non-suppression identifies corticosteroid-resistant type-2 signaling in severe asthma
per: Couillard, S, et al.
Publicat: (2021)

Mechanisms of FeNO non-suppression in severe asthma: analysis of sputum type 2 cytokines and chemokines
per: Couillard, S, et al.
Publicat: (2020)

Airway remodelling rather than cellular infiltration characterises both type2 cytokine biomarker-high and -low severe asthma
per: Khalfaoui, L, et al.
Publicat: (2022)

Sub-stratification of type-2 high airway disease for therapeutic decision-making: a ‘bomb' (blood eosinophils) meets ‘magnet' (FeNO) framework
per: Couillard, S, et al.
Publicat: (2022)

Longitudinal changes in sputum and blood inflammatory mediators during FeNO suppression testing
per: Couillard, S, et al.
Publicat: (2022)

A proof-of-concept scale to predict asthma attacks: the OxfoRd Asthma attaCk risk ScaLE (ORACLE)
per: Couillard, S, et al.
Publicat: (2021)

Utility of adherence checks in patients with severe asthma eligible for biologics: a single centre retrospective analysis
per: Oliver, ME, et al.
Publicat: (2021)

Remotely monitored therapy and nitric oxide suppression identifies nonadherence in severe asthma
per: Heaney, LG, et al.
Publicat: (2018)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
per: Howell, I, et al.
Publicat: (2024)

A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial
per: Hanratty, CE, et al.
Publicat: (2018)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
per: Shrimanker, R, et al.
Publicat: (2017)

Fluticasone furoate: CAPTAIN of fluticasones in type 2 inflammatory asthma
per: Couillard, S, et al.
Publicat: (2022)

Exacerbations of severe asthma in patients treated with mepolizumab
per: Shrimanker, R, et al.
Publicat: (2018)

Airway proteomics reveals broad residual anti-inflammatory effects of prednisolone in mepolizumab-treated asthma
per: Howell, I, et al.
Publicat: (2024)

Treatment options in type-2 low asthma
per: Hinks, TSC, et al.
Publicat: (2020)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
per: Shrimanker, R, et al.
Publicat: (2017)

Diagnostic accuracy of FeNO in asthma and predictive value for inhaled corticosteroid responsiveness: A prospective, multicentre study
per: Antonius Schneider, et al.
Publicat: (2022-08-01)

Update on the Role of FeNO in Asthma Management
per: Neveda Murugesan, et al.
Publicat: (2023-04-01)

To what extent does the prototype ORACLE scale predict treatment benefits? Predicted versus observed impact of anti-inflammatory treatments
per: Couillard, S, et al.
Publicat: (2021)

Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma.
per: Berry, M, et al.
Publicat: (2007)

How I do it: workup of severe asthma
per: Couillard, S, et al.
Publicat: (2021)

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
per: Moran, AM, et al.
Publicat: (2020)

Prognostic value of using FeNO to guide step-down treatment decisions in asthma
per: Wang, K, et al.
Publicat: (2018)

Correlation of eotaxin-3 gene expression and other IL-13-induced genes in patients with asthma
per: Couillard, S, et al.
Publicat: (2021)

The effect of oral corticosteroids on circulating type-2 cytokine producing cells in patients with severe eosinophilic asthma
per: Hynes, G, et al.
Publicat: (2018)

Interleukin-5 inhibitors for severe asthma: Rationale and future outlook.
per: Shrimanker, R, et al.
Publicat: (2017)

Does a composite score combining peripheral blood eosinophils (PBE) and exhaled nitric oxide (FeNO) accurately predict a sputum eosinophilia?
per: Connolly, CM, et al.
Publicat: (2017)

Feno and blood eosinophils as biomarkers in predicting asthma exacerbations
per: Rastogi, S, et al.
Publicat: (2017)

Emerging biologics in severe asthma
per: Pavord, I, et al.
Publicat: (2016)

Suppression of FENO with observed inhaled corticosteroid therapy in severe asthma: is it a useful test in clinical practice?
per: Shoaib Faruqi, et al.
Publicat: (2019-11-01)

The upper and lower airway microbiome in severe asthma
per: Jabeen, M, et al.
Publicat: (2022)

Biomarkers predicting response to corticosteroid therapy in asthma.
per: Brightling, C, et al.
Publicat: (2005)

Recovery of Breakthrough Asthma Attacks Treated With Oral Steroids while on monoclonal antibody therapy: protocol for a prospective observational study (BOOST)
per: Howell, I, et al.
Publicat: (2023)

FENO AND ATOPY IN PEDIATRIC ASTHMA
per: Cristiana Stanciulescu, et al.
Publicat: (2015-06-01)

Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype OxfoRd Asthma attaCk risk scaLE (ORACLE)
per: Couillard Castonguay, S, et al.
Publicat: (2022)

Reply to: inhaled corticosteroids and adult asthma
per: Beasley, R, et al.
Publicat: (2019)

The change of FeNO is correlated with asthma control and lung function
per: Yanmin Gao, et al.
Publicat: (2024-10-01)

Biological therapies for asthma
per: Couillard Castonguay, S, et al.
Publicat: (2021)

Non-eosinophilic corticosteroid unresponsive asthma.
per: Pavord, I, et al.
Publicat: (1999)

ACE2, TMPRSS2, and furin gene expression in the airways of people with asthma—implications for COVID-19
per: Bradding, P, et al.
Publicat: (2020)